Enterprise Value
-26.27M
Cash
45.5M
Avg Qtr Burn
-10.3M
Short % of Float
0.52%
Insider Ownership
8.62%
Institutional Own.
19.57%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ONCT-534 Details Cancer, Castration-resistant prostate cancer | Phase 1/2 Data readout | |
ONCT-808 (CAR-T) Details Hematologic malignancies, Cancer, B-cell lymphoma | Phase 1/2 Data readout | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Paclitaxel Details Cancer, Metastatic breast cancer | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Cancer, Mantle cell lymphoma | Failed Discontinued | |
ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details Relapsed/refractory Ewing sarcoma, Cancer | Failed Discontinued |